comparing abvd, avd & chop chemotherapy regimens in older patients with classical hl
Published 1 year ago • 1.2K plays • Length 4:42Download video MP4
Download video MP3
Similar videos
-
1:21
hodgkin lymphoma highlights from ash 2023: nivo-avd versus bv-avd in patients with hl
-
4:18
pembrolizumab monotherapy for older/abvd-ineligible patients with hodgkin lymphoma
-
1:31
abvd vs. escbeacopp in hl: a 10-year study
-
0:45
difference between quality of life & patient-reported outcomes
-
1:28
concurrent pembrolizumab and chemotherapy in classical hodgkin lymphoma
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
1:09
assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with b-cell malignancies
-
1:19
the role of chemotherapy in hodgkin lymphoma
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
1:26
promising results from the swog s1826 trial: nivo-avd versus bv-avd in patients with chl
-
0:45
optimizing chemotherapy combinations for aml
-
1:10
avenue: avelumab for classical hodgkin lymphoma
-
1:18
hodgkin lymphoma highlights at ash 2022 and future outlooks
-
1:15
swog s1826: promising results with the combination of nivolumab-avd in hodgkin lymphoma
-
2:32
updates from the avenue trial: avelumab for advanced classical hl
-
0:52
tocilizumab for aa amyloidosis
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl